S145: THE COMBINATION OF IBRUTINIB PLUS VENETOCLAX RESULTS IN A HIGH RATE OF MRD NEGATIVITY IN PREVIOUSLY UNTREATED CLL: THE RESULTS OF THE PLANNED INTERIM ANALYSIS OF THE PHASE III NCRI FLAIR TRIAL. (23rd June 2022)

• Record Type: Journal Article
• Authors: Hillmen, P.; Pitchford, A.; Bloor, A.; Pettitt, A.; Patten, P.; Forconi, F.; Schuh, A.; Fox, C.; Elmusharaf, N.; Gatto, S.; Kennedy, B.; Gribben, J.; Pemberton, N.; Sheehy, O.; Preston, G.; Howard, D.; Hockaday, A.; Cairns, D.; Jackson, S.; Greatorex, N.; Webster, N.; Dalal, S.; Shingles, J.; Cwynarski, K.; Paneesha, S.; Allsup, D.; Rawstron, A.; Munir, T.
• Is Part Of: HemaSphere. Volume 6(2022)Supplement 3
• Page Start: 46
• Page End: 47
• Publication Date: 2022-06-23
• Subjects: Hematology -- Periodicals; 616.15005
• DOI: 10.1097/01.HS9.0000843472.57904.29
• Languages: English
• ISSNs: 2572-9241